 Lymphoma, T-Cell, Cutaneous
"Lymphoma, T-Cell, Cutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
| Descriptor ID |
D016410
|
| MeSH Number(s) |
C04.557.386.480.750.800 C15.604.515.569.480.750.800 C20.683.515.761.480.750.800
|
| Concept/Terms |
Lymphoma, T-Cell, Cutaneous- Lymphoma, T-Cell, Cutaneous
- T-Cell Lymphoma, Cutaneous
- T Cell Lymphoma, Cutaneous
- Cutaneous T-Cell Lymphoma
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphomas
- Lymphoma, Cutaneous T-Cell
- Lymphomas, Cutaneous T-Cell
- T-Cell Lymphomas, Cutaneous
- Lymphoma, T Cell, Cutaneous
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Cutaneous".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Cutaneous".
This graph shows the total number of publications written about "Lymphoma, T-Cell, Cutaneous" by people in this website by year, and whether "Lymphoma, T-Cell, Cutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 | | 1995 | 2 | 0 | 2 | | 1996 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2007 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 0 | 2 | | 2012 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2017 | 2 | 0 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 2 | 0 | 2 | | 2022 | 1 | 0 | 1 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, T-Cell, Cutaneous" by people in Profiles.
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
-
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 09 01; 158(9):1031-1039.
-
Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020 05; 18(5):522-536.
-
Wang H, Wang Z, Zhang H, Qi Z, Johnson AC, Mathes D, Pomfret EA, Rubin E, Huang CA, Wang Z. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma. Mol Oncol. 2020 05; 14(5):991-1000.
-
Haverkos B. Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A hematologist's perspective. Clin Adv Hematol Oncol. 2019 02; 17 Suppl 3(2):18-20.
-
Raghavan SS, Kim J. Histopathologic approach to epidermotropic lymphocytic infiltrates. Semin Cutan Med Surg. 2018 Mar; 37(1):56-60.
-
Szczepiorkowski ZM, Burnett CA, Dumont LJ, Abhyankar SH. Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. Transfusion. 2018 04; 58(4):943-950.
-
Kremer KN, Dinkel BA, Sterner RM, Osborne DG, Jevremovic D, Hedin KE. TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL. Blood. 2017 08 24; 130(8):982-994.
-
Wang Z, Zheng Q, Zhang H, Bronson RT, Madsen JC, Sachs DH, Huang CA, Wang Z. Ontak-like human IL-2 fusion toxin. J Immunol Methods. 2017 09; 448:51-58.
-
Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? Expert Rev Hematol. 2017 Feb; 10(2):111-121.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|